What does payments for repurchase of common stock mean?

Represents the cash used to buy back shares of the company's own common stock from the open market. This is a primary method of returning capital to shareholders and can be used to offset dilution from equity compensation.

ADMA Biologics ADMA Payments for Repurchase of Common Stock

Payments for Repurchase of Common Stock at other companies

ZymeworksZYME

$76.15M—

Charles River LaboratoriesCRL

$208.29M-41.0%

Bio-Rad LaboratoriesBIO

——

HaemoneticsHAE

——

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue$114.5M-0.3%

Gross profit$80.8M+32.2%

Operating income$58.3M+67.1%

Net income$45.3M+68.5%

EPS (diluted)$0.19+72.7%

Balance sheet

See full

Cash & equivalents$138.2M+92.9%

Total debt$204.4M+2,055%

Total equity$390.3M+4.5%

Total assets$665.2M+30.3%

Cash flow

See full

Operating cash flow$58.2M+396%

CapEx$2.5M-45.9%

Free cash flow$55.7M+329%

Valuation

See full

Market cap$2.02B-54.5%

Profitability

See full

Gross margin61.3%+8.7pp

Operating margin42.1%+9.0pp

Net margin32.4%-12.6pp

FCF margin21.2%+1.4pp

Returns & leverage

See full

Return on equity43.3%-35.2pp

Debt / equity0.5×+0.5×

Current ratio7×+0.4×

Where this comes from

Reported directly by ADMA Biologics in its filing.

Tagged under the XBRL concept us-gaap:PaymentsForRepurchaseOfCommonStock.

The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about ADMA Biologics's payments for repurchase of common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ADMA Biologics's payments for repurchase of common stock?: ADMA Biologics (ADMA) reported payments for repurchase of common stock of $130.19M in Q1 2026.
What does payments for repurchase of common stock mean?: Represents the cash used to buy back shares of the company's own common stock from the open market. This is a primary method of returning capital to shareholders and can be used to offset dilution from equity compensation.